CRISPR-Cas9 for cancer therapy: Opportunities and challenges
CRISPR-Cas9 for cancer therapy: Opportunities and challenges
复制标题
DOI：
10.1016/j.canlet.2019.01.017
复制
发表时间：
2019-01-01
期刊：
影响因子：
9.7
通讯作者：
Ji, Jiansong
中科院分区：
文献类型：
--
作者：
Chen, Minjiang;Mao, Aiwu;Ji, Jiansong
癌症是一种由累积遗传/表观遗传畸变引起的遗传疾病。CRISPR-Cas9介导的基因组编辑技术已在体外和体内广泛应用于各种细胞类型和生物体中，用于有效的基因破坏和基因修饰。CRISPR-Cas9在癌症治疗方面显示出巨大的前景。然而，尽管其优点和巨大的潜力，许多挑战，如编辑细胞的适应性，编辑效率，递送方法和潜在的脱靶效应，仍然有待解决，以完全临床应用。在这里，我们介绍了CRISPR-Cas9在癌症治疗中的潜在应用和最新进展，并讨论了在临床应用中可能遇到的挑战。
Cancer is a genetic disease stemming from cumulative genetic/epigenetic aberrations. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9-mediated genome editing technology has been extensively applied in various cell types and organisms, both in vitro and in vivo, for efficient gene disruption and gene modification. CRISPR-Cas9 has shown great promise for the treatment of cancer. However, despite its advantages and tremendous potential, numerous challenges, such as fitness of edited cells, editing efficiency, delivery methods and potential off-target effects, remain to be solved for completely clinical application. Here, we present the potential applications and recent advances of CRISPR-Cas9 in cancer therapy, and discuss the challenges that might be encountered in clinical applications.